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ABSTRACT 
Objective: In this study, a facile and sensitive high-performance liquid chromatographic method for determination of nintedanib in rat plasma was 
developed and validated.  
Methods: After plasma protein was precipitated by addition of acetonitrile, the supernatant underwent centrifugation. An aliquot was then injected 
into a high-performance liquid chromatographic system with a Mightysil RP-18 GP II ODS column (250 × 3.0 mm, length by inner diameter, 5-μm 
particle size) maintained at 50 °C. A mobile phase mixture of 20 mmol phosphate buffer (pH 3.0) and acetonitrile (7:3, v/v) was used at a flow rate 
of 0.6 mL/min, with UV detection at a wavelength of 390 nm for isocratic separation and detection of nintedanib, its main metabolite (BIBF1202), 
and p-nitrophenol as an internal standard.  
Results: The quantitative range of nintedanib concentration in this method was 12.5–400 ng/ml, and the calibration curves were linear. The intra-
and inter-day accuracy values (relative errors) were in the range of −3.65%–4.00% and −3.65%–3.64%, respectively. The intra-and inter-day 
precision values (relative standard deviations) were<5.9% and 8.36%, respectively. The method was successfully applied to a pharmacokinetic 
analysis of nintedanib in rats after intravenous administration. 
Conclusion: In this study, a rapid, sensitive, and simple HPLC-UV method for the quantitation of nintedanib in rat plasma was developed and 
validated. The method was shown to be accurate and precise and was successfully applied to a pharmacokinetic study. 
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Nintedanib, methyl (3Z)-3-[[4-[methyl-[2-(4-methyl piperazine-1-
yl)acetyl]amino]anilino]-phenylmethylidene]-2-oxo-1H-indole-6-
carboxylate, is a multiple tyrosine kinase inhibitor for platelet-
derived growth factor receptor (PDGFR), fibroblast growth factor 
receptor (FGFR), and vascular endothelial growth factor receptor 
(VEGFR) [1]. The drug has significant anti-fibrotic effects, including 
inhibition of proliferation, degradation of the extracellular matrix, 
and inhibition of collagen secretion [2]. Therefore, nintedanib is 
clinically used as an anti-fibrotic drug for the treatment of idiopathic 
pulmonary fibrosis (IPF) in the EU, USA, Japan, and Switzerland 
(OFEV®) [3, 4]. 
The pharmacokinetics of several tyrosine kinase inhibitors have 
indicated the likelihood that treatment outcomes for IPF would be 
affected, and clinical studies have reported a relationship between 
clinical outcomes and tyrosine kinase inhibitor concentrations in 
plasma [5, 6]. The occurrence of adverse events, including diarrhea 
and nausea, of nintedanib are dose-dependent [7]. Thus, 
determination of nintedanib concentration in plasma is important in 
the treatment of IPF. In addition, since nintedanib is a substrate of 
multidrug resistance protein 1 (MDR1) [8], determination of 
intracellular concentrations of nintedanib in various cells that 
express the transporter is desirable.  
Recently, analytical methods using ultra liquid chromatography with 
tandem mass spectrometry (UPLC-MS/MS) have been reported for 
the determination of nintedanib in biological samples [9]. However, 
UPLC-MS/MS cannot be used for routine analysis in each laboratory 
because of its high purchase cost, high maintenance cost, and 
running costs. On the other hand, a high-performance liquid 
chromatography with ultraviolet detection (HPLC-UV) is cost 
effective and commonly used [10, 11]. HPLC-UV method for 
determination of nintedanib has also been developed [12], but the 
method has an insufficient quantitative limit of 2 µg/ml for 
nintedanib because of the method’s short detection wavelength (210 
nm). In addition, since nintedanib is rapidly metabolized to its 
metabolite BIBF 1202 [13], it is necessary to verify the separability 
of nintedanib and BIBF 1202.  
In the present study, we demonstrated a facile and sensitive HPLC-
UV method for measurement of nintedanib concentrations. In 
addition, the method was successfully applied to the 
pharmacokinetic analysis of nintedanib in rats after intravenous 
administration. 
MATERIALS AND METHODS 
Materials and animals 
Nintedanib was purchased from Cayman Chemical Co., Ltd. (Ann 
Arbor, MI, USA), BIBF 1202 was purchased from Med Chem Express 
Inc. (Monmouth Junction, NJ, USA) and p-nitrophenol was purchased 
from Wako Pure Chemicals Co., Ltd. (Osaka, Japan). All other 
reagents were commercially available and of analytical grade. Male 
Sprague–Dawley rats, 5 w old and weighing 160–180 g were 
purchased from Japan SLC (Shizuoka, Japan). The animal 
experimental protocol was approved by the Committee of the 
Laboratory Animal Center (No. H29-001) and confirmed to the 
Guiding Principles for the Care and Use of Experimental Animals at 
Hokkaido Pharmaceutical University. 
Determination of appropriate UV wavelength 
The appropriate wavelength for detection of nintedanib in the 
mobile phase described below was determined by using a UV–Vis 
spectrophotometer (UV-2550; Shimadzu, Kyoto, Japan) to scan the 
wavelengths over the range of 200–500 nm. 
Apparatus and HPLC conditions 
The chromatographic system consisted of a Shimadzu model LC-
10ATVP pump, Shimadzu model SIL-10ADvp auto-injector, and 
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Shimadzu model SPD-10Avp absorbance detector. A Mightysil RP-18 
GPII column (250 × 3.0 mm, length by an inner diameter, 5-µm 
particle size, Kanto Chemical Co., Tokyo, Japan) was used for HPLC. 
The mobile phase was a mixture of 20 mmol potassium phosphate 
buffer (pH 3.0)/acetonitrile (7:3). The isocratic separation was 
performed at a flow rate of 0.6 ml/min at 50 °C, and the column was 
monitored by UV absorbance detection at a wavelength of 390 nm. 
The sample injection volume was 20 μL, and the total run time was 
14 min. Chromatograms were integrated and processed by using an 
online computer and Chromato-Pro software version 4.0 (Run Time 
Co., Tokyo, Japan). 
Preparation of the standard and quality control solutions of 
nintedanib 
A stock standard solution (1 mg/ml) of nintedanib was prepared in 
methanol and diluted with ion-free water to prepare working 
solutions at concentrations of 0.25, 0.5, 1, 2, 4, and 8 μg/ml, 
respectively. Standard solutions (12.5, 25, 50, 100, 200, and 400 
ng/ml) of nintedanib were prepared from the working solutions by 
dilution with ion-free water. Quality control solutions used in the 
validation were prepared in the same manner as the standard 
solutions by using blank plasma collected from rats without 
nintedanib administration. An internal standard solution was 
prepared by dissolving p-nitrophenol (12 µg/ml) in acetonitrile. All 
solutions were stored at 4 °C before use. 
Sample preparation 
Plasma (80 µl) was mixed with the internal standard solution in 
acetonitrile (80 µl), followed by vortex mixing for 30 s. After mixing, 
the preparation was centrifuged at 10,000g for 5 min at 4 °C. The 
supernatant was passed through a 0.22 µm filter (Millex-GV, 
Millipore Co., Billerica, MA, USA), and the filtrate was injected into 
HPLC system.  
Pharmacokinetic experiments in rats 
Nintedanib dissolved in 0.1 M HCl was administered intravenously 
at a dose of 25 mg/0.5 ml/kg. At each designated time point, the rats 
were anaesthetized by using intraperitoneal injections of sodium 
pentobarbital and butorphanol tartrate at doses of 50 and 5 mg/kg, 
respectively, and blood was collected from the jugular vein. The 
samples were stored at −30 °C before measuring the drug 
concentrations. The concentrations of nintedanib were measured in 
each sample by HPLC as described above. 
Pharmacokinetic analysis 
The pharmacokinetic analysis was performed by using the non-
compartmental analytical method. The terminal elimination rate 
constant (β) for the drug concentration-time curves after 
intravenous administrations were determined by linear regression 
of the data points from the terminal portion of the complete 
concentration-time plots. The area under the drug concentration-
time curve (AUC) was calculated by using the logarithmic 
trapezoidal rule up to the last measured drug concentration [C 
(last)] and extrapolated to infinity by addition of a correction term 
[C (last)]/β. The area under the first moment curve (AUMC) to the 
last measured drug concentration was calculated by using the linear 
trapezoidal rule and the addition of the correction term after the last 
measured point to infinity {[C (last)] × [C (last)]/β}. The terminal 












Where F is the absolute bioavailability. The mean resident time 





The volume of distribution space (Vd) was calculated by using 
equation (4): 
Vd =  CLtot  ×  MRT (4) 
RESULTS 
Selection of analytical wavelength 
To determine the absorbance wavelength for UV detection of 
nintedanib, the UV spectrum of nintedanib was acquired, as shown 
in fig. 1. The maximum absorbance of nintedanib was found to occur 




Fig. 1: UV spectrum of nintedanib (10 µg/ml) in the mobile 
phase for HPLC 
 
Specificity 
A typical elution pattern of nintedanib and its main metabolite (BIBF 
1202) and internal standard (IS) in this method is shown in fig. 2. 
The peaks of nintedanib, BIBF 1202, and IS were completely 
separated (fig. 2A) and exhibited retention times of 12, 3.9, and 6.6 
min, respectively. No interfering peaks were seen in the plasma 
blank (fig. 2B). At the same time, nintedanib, BIBF 1202, and IS were 
detected in the plasma after intravenous administration in rats (fig. 
2C). In addition, to evaluate potential interference by the drugs 
listed in the IPF treatment guideline (12), including pirfenidone, 
prednisolone, bosentan, ambrisentan, macitentan, N-acetyl-L-
cysteine, sildenafil, and warfarin, blank plasma samples spiked with 
these drugs were analyzed by HPLC. No interfering peaks were 
observed under the HPLC conditions fused for nintedanib 
determination (data not shown). 
Linearity 
Calibration curves were constructed from the relationship (Y = 
aX+b) between the peak area ratio (Y) of nintedanib to IS versus 
nintedanib concentration (X). A least-squares linear analysis method 
was used to determine the slope, intercept, and correlation 
coefficient. Good linearity was indicated over the concentration 
range of 12.5 to 400 ng/ml for nintedanib (r = 0.9997). The 
regression curve was Y = 0.00281*X+0.0024. The limit of detection 
(signal-to-noise ratio ≥ 3) for nintedanib was calculated to be 4 
ng/ml.  
Accuracy, precision, and recovery 
The reproducibility of the analytical method for determination of 
nintedanib concentrations was evaluated by determining the intra-
and inter-day variances. The accuracy and precision data in this 
method are shown in table 1. The intra-and inter-day accuracy 
values (relative error) were in the range of −3.65%–4.00% and 
−3.65%–3.64%, respectively. The intra-and inter-day precision 
values (relative standard deviation) were<5.95% and 8.36%, 
respectively. The recovery for nintedanib from rat plasma was>92%. 
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Fig. 2: Representative chromatograms of nintedanib. (A) nintedanib (400 ng/ml), its main metabolite (BIBF 1202, 400 ng/ml), and 
internal standard (IS, 6 µg/ml) dissolved in the mobile phase; (B) blank rat plasma; (C) real plasma samples of nintedanib in rats after 2-h 
intravenous administration of nintedanib (20 mg/kg wt) 
 




Measured concentration (ng/ml) Accuracy (RE %) Precision (RSD %) 
12.5 12.7±0.8 1.36  5.95  
25 26.0±0.6 4.00  2.27  
50 48.2±2.7 -3.65  5.70  
100 100.4±5.9  0.45  5.83  
200 199.0±8.4  -0.51  4.24  




Measured concentration (ng/ml) Accuracy (RE %) Precision (RSD %) 
12.5 12.9±1.1 3.07  8.36  
25 25.9±0.8 3.64  2.91  
50 48.2±3.0 -3.65  6.17  
100 98.1±7.2  -1.94  7.34  
200 199.7±7.6  -0.17  3.83  
400 414.6±21.9  3.64  5.28  
Each data represents the mean±SD (n = 5)., RE: relative error., RSD: relative standard deviation. 
 
Application to pharmacokinetic analysis 
The analytical method in this study was applied to the determination 
of nintedanib concentrations and calculation of pharmacokinetic 
parameters. The time courses of the nintedanib concentrations in 
plasma following intravenous administration in rats are shown in 
fig. 3. The pharmacokinetic parameters calculated by non-
compartmental analysis are shown in table 2.  
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Fig. 3: Time profile of nintedanib in rat plasma after intravenous administration. Nintedanib (20 mg/kg wt) was administered 
intravenously to rats. At each time point (7.5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 12 h) after administration, plasma was 
collected, and the nintedanib concentrations in each sample were determined. Each data represents the mean±SD (n = 4) 
 
Table 2: Pharmacokinetic parameters of nintedanib in plasma after intravenous administration to rats 
Pharmacokinetic parameter   
AUC0-∞ (ng*h/ml) 3921±293 
MRT0-∞ (h) 5.84±0.40 
kel (h-1) 0.119±0.014 
T1/2 (h) 5.91±0.67  
Vdss (l/kg) 41.8±5.4  
CL (l/h/kg) 5.30±0.47  
Each pharmacokinetic parameter was calculated from the data shown in fig. 3., The values represent the mean±SD (n = 4). 
 
DISCUSSION 
In this study, we described a rapid, simple, and sensitive HPLC-UV 
method to the determination of nintedanib in rat plasma. Nintedanib 
levels in plasma detected by HPLC-UV have been previously 
reported by Purnachand et al. [12]. However, our method was able 
to simultaneously detect nintedanib and its main metabolite 
(BIBF1202) (fig. 2). Furthermore, we improved the lower limit of 
quantification of HPLC-UV by this method. The value of the lower 
limit of quantification by using the previous HPLC-UV method was 2 
µg/ml, whereas its value by using this method was 12.5 ng/ml (table 
1). This quantitative sensitivity is sufficient to determine nintedanib 
concentrations in plasma after oral administration of a clinical 
dosage to humans [7].  
In some pharmacokinetic studies, nintedanib concentration in 
biological samples has been measured by liquid chromatography 
with tandem mass spectrometry [9, 13, 15, 16]. Overall, a 
bioanalytical method such as LC-MS/MS possesses a smaller value 
for the lower limit of quantification than methods such as HPLC-UV. 
However, LC-MS/MS systems are expensive and not generally 
available.  
Therefore, HPLC-UV systems are more commonly used across 
laboratories for drug analysis of biological samples. Additionally, 
this analytical method requires simpler chromatographic 
conditions, including the use of simple mobile phases with small 
percentages of organic solvent in the absence of gradient 
programs. Moreover, this method has an easier preparation step 
for plasma samples: plasma proteins are precipitated by the 
addition of acetonitrile, following which the supernatant is 
subjected to centrifugation. 
Thus, we evaluated the pharmacokinetics of nintedanib in rats using 
this enhanced HPLC-UV method (fig. 3 and table 2). The Vdss value 
(41.8 L/kg) indicated that nintedanib was distributed widely in 
several organs. According to the previous study by Xu et al. [17], 
nintedanib concentrations in various organs including the liver, 
spleen, lungs, kidneys, and thymus were higher than those in plasma 
after oral administration in rats, supporting our findings. 
CONCLUSION 
In this study, a rapid, sensitive, and simple HPLC-UV method for the 
quantitation of nintedanib in rat plasma were developed and 
validated. The method was shown to be accurate and precise and 
was successfully applied to a pharmacokinetic study.  
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